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Acetaminophen (N-acetyl-p-aminophenol; APAP 1 ; Paracetamol) is the most commonly used drug for the treatment of pain and fever. Although safe at therapeutic doses, in overdose, acetaminophen produces severe hepatotoxicity. The mechanism of toxicity is by initial metabolism to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450 . At therapeutic doses, the reactive metabolite is detoxified by glutathione, but following overdoses, glutathione is depleted and the metabolite covalently binds to proteins as 3-(cystein-S-yl)-acetaminophen (APAP-CYS) (Streeter et al., 1984) . Covalent binding to protein is thought to be a critical step in the development of hepatotoxicity.
A number of methods have been used to quantify the amount of acetaminophen covalently bound to proteins. In initial studies showing the correlation between acetaminophen toxicity and covalent binding, Jollow and coworkers (1973) used radiolabeled acetaminophen. Subsequently, polyclonal antisera were raised that recognized the acetaminophen-cysteine adducts (Bartolone et al., 1987; Roberts et al., 1987) , and the relationship between covalent binding and toxicity was studied extensively. coworkers (1989, 1990 ) developed a competitive enzyme-linked immunosorbent assay to quantify acetaminophen covalent binding in the liver and serum of treated mice. In addition, Western blot assays were performed. Although these latter assays were not quantitative, they were useful in comparing the relative amounts of adduct in proteins (Bartolone et al., 1988; Pumford et al., 1990; Matthews et al., 1996) . These assays yielded valuable new information concerning the mechanism of acetaminophen toxicity but have had limited clinical application since the antibodies are not readily available and the assay was relatively insensitive for the measurement of acetaminophen-cysteine in human sera of acetaminophen overdose patients (James et al., 2001) .
The following article describes the development of a high-performance liquid chromatograph with electrochemical detection (HPLC-ECD) method to quantify acetaminophen-cysteine in proteins. Acetaminophen-and glutathione-derived metabolites have previously been assayed by HPLC-ECD methods (Riggin et al., 1975; Munson et al., 1978; Miner and Kissinger, 1979; Hall et al., 1986; Whitcomb and Block, 1994; Alonso et al., 1995; Bonkovsky, 1995; Rivera-Penera et al., 1997) . The advantage of the HPLC-ECD assay for acetaminophen-cysteine in proteins is its ability to quantify conjugates in serum protease digestion. Serum samples from mice were dialyzed under the same conditions as described above, with the exception that samples were diluted 1:10 before dialysis. Human serum samples were not diluted before dialysis. To confirm that dialysis removes potential, contaminating free APAP-CYS from protein bound APAP-CYS adducts, liver samples from saline-treated animals were spiked with 10 mM APAP-CYS and incubated at 25°C for 10 min. Samples were then dialyzed for 30 h, as described above, or received an additional 30-h dialysis. A portion of these dialysates was treated with and equal volume of 40% trichloroacetic acid. The resulting precipitate was washed twice with Na 2 HPO 4 , pH 7.4, then resuspended in 10 mM sodium acetate.
Protease Digestion. Protease digestion was performed according to previously published methods (Hensley et al., 1997; Walker et al., 2000) with some modification. Briefly, a solution of protease (8 U/ml) was dialyzed as described above to remove contaminating amino acids and stored at Ϫ80°C. Dialyzed proteins samples were mixed with an equal volume of dialyzed protease and incubated at 50°C for 18 h. After protease digestion, the samples were diluted 1:2 with 40% trichloroacetic acid to precipitate residual protein.
The samples were placed on ice for 10 min and then centrifuged at 16,000g for 10 min. Supernatants were filtered through 0.2-m, polyvinylidene difluoride, Microfuge filter tubes immediately before analysis by HPLC. Samples were diluted in 20% TCA in 10 mM sodium acetate for HPLC analysis of L-tyrosine concentrations (serum, diluted 1:50; liver, diluted 1:250).
HPLC-ECD Analysis. Analysis was performed at room temperature under isocratic conditions using a model 582 solvent delivery system and two model 5600A CoulArray detectors from ESA (Chelmsford, MA). Automated injection (25 l) was performed using a model 712, Waters Intelligent sample processor (WISP) from Waters Corp. (Milford, MA). The mobile phase was 50 mM sodium acetate and 7% methanol, pH 4.8. The flow rate was 1.0 ml/min through a reversed-phase TSK-GEL-ODS-80Tm column (4.6 mm ϫ 25 cm; TOSOHASS, Montgomeryville, PA). Run time was 27 min. The peak detection limit was set at 100 pA, with an acceptable retention window error of 4%. Two CoulArray cell detectors (four electrodes/cell) were placed in series. In initial experiments, electrode potentials from 100 to 990 mV were divided between the eight electrodes. From the eight resulting currents, three were chosen that would detect L-tyrosine (leading, dominant, and following channels) and three that would detect APAP-CYS. A ratio analysis of the three channels along with retention time were used to identify L-tyrosine and APAP-CYS in unknown samples. Ratio 1 used the leading and dominant channels and compared the ratios of the peak heights for the standards to that of the unknown. Ratio 2 used the dominant and following channels. The closer the ratios are to 1 the greater the probability of identity. Hensley and coworkers (1997) describe this technique in detail. The optimal potentials for the analysis (channels 1-6) were 155, 280, 125, 460, 500, and 550 mV. L-Tyrosine was detected on channels 4, 5, and 6, whereas APAP-CYS and APAP were detected on channels 1, 2, and 3. Once identified using ratio analysis and retention time, L-tyrosine and APAP-CYS in unknown samples were quantified using peak height of the dominant channel and standard curves for L-tyrosine and APAP-CYS. APAP was never detected in dialyzed samples. Stock solutions of APAP-CYS and L-tyrosine were prepared in 0.2 N HCL. Serial dilutions of a solution containing both APAP-CYS and L-tyrosine were prepared from 0.039 to 20 M in 20% TCA/10 mM sodium acetate to generate standard curves. APAP-CYS values in unknown samples were expressed as moles of APAP-CYS per 100 mol of tyrosine. By normalizing the data to released L-tyrosine, values are not dependent in the degree of protease digestion.
Statistics. Ratio analysis and concentration determinations were made using CoulArray for Windows Data Processing Module, version 1.01 (ESA, Inc.). Data are expressed as mean Ϯ S.E.M. unless noted otherwise. Statistical analysis was by analysis of variance followed by the Newman-Keuls test. Linear regression analysis was performed using Prism (GraphPad Software, Inc., Sand Diego, CA) and the Pearson correlation. Statistical significance was set at P Ͻ 0.05. 
Results

HPLC-ECD Analysis of L-
. HPLC-EC Analysis of APAP-CYS.
A, A solutions containing tyrosine, APAP, and APAP-CYS (1 M each, 25-l injection) was analyzed by HPLC-EC. All eight electrode potentials are shown. Tyrosine eluted at 6.5 min, APAP-CYS at 22.9 min, and APAP at 25.5 min. B, shown is a representative chromatogram of a sample of liver from a saline-treated animal. No peaks corresponding to APAP-CYS or APAP were detected for any sample from saline-treated animals. Potentials from channels 1, 2, and 3 are shown. C, shown is a representative chromatogram of a sample of liver from an APAP-treated animal (300 mg/kg, 60 min). Potentials from channels 1, 2, and 3 are shown. Peak ratios were consistent for APAP-CYS at a retention time of 22.9 min. APAP was not detected in samples subjected to dialysis before hydrolysis.
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at ASPET Journals on September 8, 2017 dmd.aspetjournals.org variation (CV) for the slope was 16.5% (n ϭ 10 curves). CV for the 0.625 and 10 M standards was 29 and 16% respectively. For APAP-CYS, CV for the slope was 13% (n ϭ 12 curves). CV for the 0.625 and 10 M standards was 13.5 and 13%, respectively. The lower limit of detection for each compound was approximately 0.8 pmol/25-l injection at a signal-to-noise ratio of 3.
Analysis of APAP-CYS Protein Adducts in Mice. Liver and blood samples were collected from mice 2 h after administration of saline or APAP (300 mg/kg ip). Protein samples were dialyzed extensively before protease digestion to remove nonprotein bound APAP-CYS and APAP and its metabolites, such as APAP mercapturate or APAP-glutathione conjugates. Figure 1 , B and C, shows representative chromatograms of protease-digested liver protein from saline-treated and APAP-treated mice, respectively. Channels 1 (155 mV), 2 (280 mV), and 3 (125 mV) were used to detect APAP-CYS and APAP. Neither APAP-CYS nor APAP was ever detected in saline-treated animals (Fig. B) . Although APAP-CYS could be detected in APAP-treated animals, APAP was never detected in dialyzed protein samples (Fig. C) .
Both retention time and peak ratio were used to define whether the unknown peaks were consistent with the standard (APAP-CYS). Retention times for the metabolite and standard APAP-CYS were consistent throughout all runs. The average retention time for APAP-CYS was 22.71 Ϯ 0.40 min (mean Ϯ S.D.; n ϭ 10) Average retention time for tyrosine was 6.45 Ϯ 1.02 min (mean Ϯ S.D.; n ϭ 10). Quantitation of the amount of metabolite was performed based on comparison of peak heights of the metabolite on channel 2 with a known standard curve of peak height (channel 2; standard APAP-CYS) versus concentration.
FIG. 2. APAP-CYS in liver and serum of APAP-treated mice.
Mice treated with APAP (300 mg/kg i.p.) (n ϭ 5) were sacrificed at designated times. Samples of liver were analyzed for APAP-CYS and GSH (A). Samples of serum were analyzed for APAP-CYS and ALT levels (B). Data are expressed as mean Ϯ S.E.M. ખ, p Ͻ 0.05 compared with the saline control group (time 0).
FIG. 3. APAP-CYS in human serum samples.
A, linear regression analysis of APAP-CYS in sera versus serum AST levels in APAP overdose patients (Pearson r, 0.831; p Ͻ 0.05). Two points overlap at APAP-CYS levels of zero. Dotted lines indicate the 95% confidence interval. B, linear regression analysis of the time to treatment with N-acetylcysteine versus APAP-CYS in sera (Pearson r, 0.607; P Ͻ 0.05). Dotted lines indicate the 95% confidence interval. Symbols indicate estimated dose of APAP: Յ225 mg/kg (squares), 226 Յ 350 mg/kg (diamonds), Ͼ350 mg/kg (circles). 
Analysis of APAP-CYS Protein Adducts in APAP-Treated Mice.
A time course for the formation of APAP-CYS protein adducts and GSH depletion in liver and serum APAP-CYS protein adducts and ALT levels were determined in mice treated with APAP (300 mg/kg). Figure 2A shows APAP-CYS protein adducts and GSH levels in the liver. As GSH levels fell, APAP-CYS increased. APAP-CYS protein adducts were detected 15 min after administration of APAP and increased approximately 20-fold from 0.035 Ϯ 0.005 to 0.800 Ϯ 0.150 mol of APAP-CYS/100 mol of tyrosine by 120 min. During this time period, GSH levels declined approximately 80%. Figure 2B shows APAP-CYS protein adducts and ALT activity in the serum of the same mice. As expected, serum ALT activity did not change over the 2-h time course. However, APAP-CYS protein adducts were detected 15 min after administration of APAP and were increased approximately 20-fold from 0.022 Ϯ 0.005 to 0.418 Ϯ 0.046 mol of APAP-CYS/100 mol of tyrosine by 120 min. These amounts, approximately 0.05 nmol/mg of protein and 1 nmol/mg of protein [based on the estimated abundance of tyrosine in protein of 3.2% (Doolittle, 1989) ] are similar to values previously reported using the competitive enzyme-linked immunosorbent assay .
Two types of experiments were performed to validate that the assay measured APAP-CYS protein adducts and not free APAP-CYS. In the first, authentic APAP-CYS was added to serum from mice that had not received acetaminophen. The serum was then dialyzed 30 h, treated with protease, and assayed by HPLC-EC for APAP-CYS adducts. APAP-CYS was not detectable in these samples, indicating that dialysis efficiently removed free APAP-CYS (data not shown). In the second experiment, serum obtained from the mice 15 min after administration of APAP was subjected to extended dialysis. Table 1 shows that detected APAP-CYS did not change even after 60 h of dialysis. Furthermore, all detectable APAP-CYS was accounted for in the TCA precipitate. These data show protease digestion of dialyzed or TCA-precipitated serum measures APAP-CYS protein adducts.
APAP-CYS Adducts in Human Overdose Patients. Mean values of APAP-CYS adducts, AST, and ALT for overdose patients by hepatotoxicity severity group are listed in Table 1 . No adducts were detected in control subjects (humans with no recent therapeutic or toxic APAP exposure). From linear regression analysis, positive linear relationships were found for APAP-CYS adduct concentration and AST levels ( Fig. 3A; Pearson r, 0.831; P Ͻ 0.05). Thus, the large majority of patients fell within the 95% confidence interval. Only one patient was dramatically out of this range (Fig. 3A) . It is unclear whether this patient had other pathology that may have lead to an increased AST level. Also, there was a significant correlation between APAP-CYS adduct concentration and the time from the acetaminophen ingestion to therapy ( Fig. 3B; Pearson r, 0.607; P Ͻ 0.05).
APAP-CYS adducts were detected in patients even with relatively mild hepatotoxicity, as measured by AST and ALT levels ( Table 2) .
Discussion
Studies in the mouse have revealed that APAP-CYS adducts are excellent biomarkers of acetaminophen toxicity. Initial data using radiolabeled acetaminophen suggested that adducts are formed only under conditions of toxicity (Jollow et al., 1973 (Jollow et al., , 1974 . Subsequently, these findings were confirmed using immunochemical assays (Roberts et al., 1987; Pumford et al., 1989; Birge et al., 1990; Pumford et al., 1990) . Similarly, data in adult overdose patients also indicated that APAP-CYS adducts detected immunologically correlated with development of significant hepatotoxicity (ALT activity Ͼ 4000 IU/l) (Birge et al., 1990; Hinson et al., 1990; James et al., 2001) .
In the present study, we have developed an assay for APAP-CYS protein adducts that uses HPLC and electrochemical detection. This assay is highly specific, extremely sensitive, and does not require specific antibodies that are generally unavailable. Thus, the assay may have general utility. Protein samples are enzymatically hydrolyzed and APAP-CYS released from protein is separated by HPLC and detected by an electrochemical method. Another advantage is that the assay uses tyrosine as an internal standard, eliminating the need to determine the absolute amount of protein hydrolyzed. This assay also can detect and quantify APAP, as others have previously reported (Riggin et al., 1975; Munson et al., 1978; Miner and Kissinger, 1979) . However, dialysis or protein precipitation before proteolysis is effective in removing any contamination of free compounds.
Using this assay, we demonstrated that APAP-CYS adducts are generated in the liver and serum of mice before detectable increases in serum transaminase levels occur. With a competitive immunoassay, APAP-CYS adducts were detected in serum only after significant increases in serum ALT levels (Pumford et al., , 1990 ). An overdose of APAP depletes liver GSH because GSH is an effective scavenger of NAPQI. We observed a 60% decrease in liver GSH content at the time APAP-CYS adducts began to appear. This is consistent with the concept that NAPQI will react with cysteine when GSH is depleted.
Also, we have used this assay to analyze samples obtained from APAP-overdosed patients. Western blot analysis only detected APAP-CYS adducts in serum when ALT activity exceeded 6000 IU/l (James et al., 2001) . Analyzing these same serum using the HPLC-EC method, APAP-CYS adducts were detectable in serum of patients who overdosed with APAP even though the patients may not have had large increases in serum AST or ALT levels. Thus, the HPLC-EC assay seems to be more sensitive than immunological assays. There was a significant correlation between serum AST levels and serum APAP-CYS protein adducts. Furthermore, there was a significant correlation between serum APAP-CYS protein adducts and time to treatment. Additional studies are needed to assess the effect of N-acetylcysteine therapy on APAP-CYS adduct formation over time. The development of this assay provides a tool for the systematic study of APAP toxicity in humans following toxic exposures or therapeutic misadventures with APAP. Recent literature has highlighted the occurrence of therapeutic misadventures with APAP (Seeff et al., 1986; Eriksson et al., 1992; Bonkovsky et al., 1994; Whitcomb and Block, 1994; Rivera-Penera et al., 1997; Heubi et al., 1998) . These articles describe the development of hepatotoxicity in patients using APAP with therapeutic intent. Although the development of toxicity in the setting of therapeutic intent is poorly understood (Prescott, 2000) , several frequently cited risk factors include dose miscalculation or lack of age appropriate dose formulation (RiveraPenera et al., 1997; Heubi et al., 1998) , alcoholism (Eriksson et al., 1992; Johnston and Pelletier, 1997) , malnutrition with associated depletion of glutathione (Bonkovsky et al., 1994) , and concurrent therapy with drugs known to cause CYP2E1 induction (Wilson et al., 1978; Murphy et al., 1990) . The development of this assay may be helpful in delineating the relative contribution of APAP covalent binding to the development of toxicity in these clinical settings and establishing whether serum levels of APAP-CYS early after APAP ingestion can be used as a predictor of the severity of hepatotoxicity. In addition, this assay may be useful in the diagnostic evaluation of patients with acute hepatic failure of indeterminate etiology for which APAP toxicity is suspect.
